In Brief: Perkin-Elmer/Hyseq
This article was originally published in The Gray Sheet
Executive Summary
Perkin-Elmer/Hyseq: Firms ink strategic partnership agreement to commercialize DNA microchip technology which includes a $10 mil. equity investment in Hyseq by Perkin-Elmer, P-E announces June 19. Under the terms of the deal, both firms will invest additional research funds in Hyseq's proprietary DNA HyChip technology. Combination of the HyChip technology with P-E DNA analysis technologies is anticipated to enable creation of a DNA chip "that can assay any genetic target through the use of specially designed reagents and software," P-E says. P-E will have exclusive worldwide rights to commercialize sequencing systems using the HyChip technology under the agreement...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.